drugset / Trial / NCT07398261

Efficacy of Mirabegron for Treatment of Non-monosymptomatic Nocturnal Enuresis in Children

NCT07398261

Phase 3 Active not recruiting 151 enrolled Menoufia University
RandomizedParallel-groupSingle-blindTreatment

Summary

This phase 3 clinical trial will compare use of individual treatment with mirabegron or desmopressin and their combination for treatment of non-monosymptomatic nocturnal enuresis in children

Timeline

Start
2023-08-28
Primary completion
2026-09-01
Completion
2026-11-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Mirabegron Other / unclassified 25 mg Oral

Indications